RE:ImmunityBio stock price Immunity Bio is doing a combination trial with both BCG plus their drug N-803. 2 drugs and 15 treatments and maintenance treatments to follow. Very good results as 72% show a CR at any time ( between 3-6 months) and 59% of those patients maintain their CR status for 12 or more months. So 59% of 72% is equal to a 42% 12 or 15 months CR rate excellent and beats Vicinium and Keytruda. One can't compare combination treatments to a single agent, because it's expected to give better results than each drug alone however we may hit up to 94% CR at any time and hopefully maintain over 42% CR at 12 months or more. If we had to combine TLD-1433 with N-803 or Keytruda, we would maybe get 100% CR, but who knows we get get close to that as a single agent One time treatment with a 6 months maintenance? I'm not worried, because it's not comparable,but for sure it will be competition that if we match or beat in efficacy, then we will still have the advantage of being safer and only one treatment Vs 15 or more. Just IMO
Camphikefish wrote: Hoping Enrique or someone can expand on the 72% CR ImmunityBio reported from their phase 2 150 + patient NMIBC trial as it relates to their current stock price . With so many patients disease free at 12 months it seems this stock would've gone sharply higher . I tried my best to research, read, and understand before this posting however, I realize I need to be enlightened ! Honestly I had never heard of this stock before someone posted about it yesterday or the day before . It concerns me . Please put me at ease !